About us

Oviva is Europe’s leading digital health provider for weight-related conditions. We make this care accessible to everyone who needs it – reimbursed, at scale, and proven.

Founded in 2014 by Kai Eberhardt and Manuel Baumann, we’ve significantly improved the lives of more than 1 million patients across Germany, the UK, and Switzerland, backed by 100+ peer-reviewed publications.

Our AI-enabled care combines a medical-device-certified app with clinical teams of doctors, dietitians, and behavioural specialists: reimbursed as a certified DiGA in Germany, in partnership with the NHS in the UK, and integrated into Swiss public healthcare. We treat obesity, hypertension, and type 2 diabetes, expanding further to become the long-term partner for chronic care in Europe.

Our mission: To build a healthier future for all, our mission is to provide the most accessible and effective care to people living with weight-related conditions

Why? Patients live healthier lives. Health systems become more sustainable. Societies remain healthier and more productive. We prove it by rigorously measuring and publishing our outcomes.

Meet Renata

The best way to make our vision more tangible is to tell you about one of our most active patients, Renata. She started with us in 2017, when she became aware of high cholesterol in a routine checkup, after living with obesity and weight-related knee pain for years. Her results are nothing short of incredible. She lost 17kg, kept it off, normalised her cholesterol levels, and now loves taking long walks with her dog, Benedikt.

The history of Oviva

2014

Oviva is founded by Kai Eberhardt and Manuel Baumann.

We employ the first dietitian in Switzerland.

The first person is treated, supported by our app.

2015

We open our first office outside Swiss borders: in London, United Kingdom (UK).

People begin to notice us: we sign our first contracts with a doctor and a health insurance provider in Switzerland, and the NHS in the United Kingdom.

2016

We open an office in Potsdam, Germany – our third site.

We complete our $800k seed round.

We launch our type 2 diabetes service in the UK.

The team grows to over 50 people.

By the end of this year, we’re already working with 100+ doctors and clinics across Europe.

2017

Three’s not enough – so we open our fourth site, in Paris, France.

To continue to drive our growth we close a $11 million Series A financing round.

2018

Our first Oviva Clinic (T3 weight management) opens in the UK on a local level.

We now scaled to 150 employees, 50,000 patients treated, and 1’000+ referring doctors.

We win first prize at the Forum of Managed Care (FMC) and become recognized as a “Model of Good Practice” by the Swiss Federal Office of Public Health.

2019

We launch our NHS Diabetes Prevention Programme (NDPP) in the UK.

End of year we complete another $21 million Series B financing round (finalized early 2021).

2020

We launch the national diabetes remission service in the UK.

We now scaled to 300 employees, 100,000+ patients treated, and 5’000+ referring doctors.

In Germany, we reach a milestone and begin our first collaboration with a German health insurer.

2021

We sign our first partnership agreement with a French health insurer.

We complete our $80 million Series C financing round; one of the largest rounds in the European digital health sector.

Our first digital health application (or DiGA), Oviva Direkt for obesity, is included in the DiGA directory of the German Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) in October.

We end the year with 600 employees and over 200’000 patients treated. What a year!

2022

Scaling of Oviva’s digital therapeutic product, Oviva Direkt – a German DiGA.

Winner of the 2022 HSJ Partnerships Award for the ‘Most impactful project addressing health inequalities’ for our Type 2 diabetes structured education program delivered in partnership with NHS North East London.

Expansion of our range of therapies in Switzerland: Our patients can now also take advantage of our app-guided psychotherapy to improve their health in the long term.

By the end of the year, we had treated more than 300,00 patients and further expanded our partnerships with doctors, clinics, and health insurers throughout Europe.

2023

We now have treated more than 500’000 patients.

Oviva Direkt in Germany receives permanent DiGA listing.

We get recommended by NICE (National Institute for Health and Care Excellence) to deliver digital Tier 3 Weight Management services with weight loss medications within the NHS.

2024

We surpass 800’000 patients treated across Europe.

We expanded our services to provide even more holistic care for our patients. With the launch of the virtual Oviva Clinics in the United Kingdom and Switzerland, we offer medical support therapy.

2025

We have now supported over 1 million patients across Europe and are expanding care for over 30,000 doctors.

Oviva announces breakthrough top-line results from two key clinical trials (HYPED & AMODA), proving our digital health applications for obesity and hypertension significantly outperform standard care alone.

Featured across multiple major UK publications, a study of 700 NHS patients demonstrates that Oviva’s digital support cuts workplace sick days by 50% and significantly reduces healthcare visits.

2026

Our hypertension digital health application (or DiGA) is included in the DiGA directory of the German Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) in January.

We complete our €200 Million Series D financing round to expand access to chronic care, led by long-term, impact-focused healthcare investors.